Brief: Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination
02/06/2025 21:36
June 2 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: JAZZ PHARMACEUTICALS ANNOUNCES ZEPZELCA® (LURBINECTEDIN) AND ATEZOLIZUMAB (TECENTRIQ®) COMBINATION SIGNIFICANTLY IMPROVES SURVIVAL AS FIRST-LINE MAINTENANCE THERAPY FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER JAZZ PHARMACEUTICALS PLC - COMBINATION THERAPY REDUCES DISEASE PROGRESSION OR DEATH RISK BY 46% Source text: ID:nPn1JghhTa Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032